DexCom earnings beat by $0.03, revenue topped estimates
Cathie Wood’s ARK ETFs have reported their daily trades for Thursday, April 3rd, 2025, revealing a mix of significant buying and selling activity across the technology and healthcare sectors. The trades indicate ARK’s ongoing strategy adjustments and portfolio rebalancing efforts.
Topping the list in terms of dollar value, ARK sold a substantial 343,381 shares of UiPath Inc (NYSE:PATH), a leading enterprise automation software company. The shares were sold across two of its funds, ARKW and ARKF, totaling approximately $3,715,382. This move comes after a series of sales in the PATH stock, suggesting ARK may be reducing its exposure to the automation sector or taking profits after previous accumulations.
On the buying side, ARK continued to increase its position in Robinhood Markets Inc (NASDAQ:HOOD), purchasing another 36,250 shares through its ARKK ETF, valued at $1,547,150. The consistent buying pattern over the past week shows ARK’s growing conviction in the online brokerage platform, despite the company’s past controversies and market volatility.
Additionally, ARK invested in 27,431 shares of GitLab Inc (NASDAQ:GTLB), a complete DevOps platform, across its ARKK and ARKW ETFs, amounting to $1,325,740. This purchase aligns with ARK’s trend of accumulating GTLB shares, signaling strong confidence in the company’s growth prospects within the software development industry.
In a smaller transaction, ARK offloaded 119,913 shares of Repare Therapeutics Inc (NASDAQ:RPTX), a precision oncology company, through its ARKG ETF for a total of $128,306. This sale is part of a series of reductions in RPTX holdings, indicating a strategic shift or risk management measure for ARK’s exposure to the biotechnology sector.
Investors and market watchers closely monitor ARK’s daily trades, as Cathie Wood’s investment decisions often set trends and influence market movements. The continuous adjustments in ARK’s ETF portfolios reflect the firm’s active management approach and its commitment to capitalizing on disruptive innovation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.